Alkem's Revolutionary therapy TERIPARATIDE-GEMFRAC for weak bones now more accessible to all Indians

This reduction is expected to benefit a broader patient population, improving osteoporosis management in India.

Teriparatide, a recombinant fragment of human parathyroid hormone (N-terminal 34 amino acids), is a powerful osteoanabolic agent. Multiple clinical trials have confirmed its safety and effectiveness in treating osteoporosis.

Alkem Labs Management said, “At Alkem, we believe advanced healthcare should be accessible to all. With Gemfrac, India’s most affordable Teriparatide, we are redefining osteoporosis care by making this gold-standard treatment more affordable for millions. With over 61 million Indians affected by osteoporosis & 80% of which are women, access to effective treatment is crucial. By significantly reducing costs, we aim to improve treatment adherence and reduce fracture risks. This initiative reflects our unwavering commitment to affordable innovation and patient-first healthcare solutions”.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alkem labs.